Advanced search

Vol 27, No 6 (2020)
Review Article
Published online: 2019-02-20

open access

View PDF Download PDF file
Page views 2963
Article views/downloads 2844
Get Citation

Connect on Social Media

Connect on Social Media

Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension

Katarzyna Cierpka-Kmieć1, Dagmara Hering1
DOI: 10.5603/CJ.a2019.0021
Pubmed: 30799548
Cardiol J 2020;27(6):857-867.

Abstract

Early detection and management of elevated blood pressure is crucial in reducing the burden of cardiovascular disease (CVD). The importance of an absolute risk assessment and patient risk stratification has been highlighted in the European hypertension guidelines since 2003. Amongst numerous risk factors influencing patient prognosis, elevated heart rate (HR) has been indicated as important predictor of future risk of hypertension, coronary heart disease, sudden cardiac death, heart failure, CVD, stroke, total cancer and mortality. Given that resting HR can be easily determined in clinical practice and modified by lifestyle changes as well as beta-blocker therapy, it seems reasonable that lowering resting HR should be a potential target to reduce disease burden and premature mortality. However, there is a lack of outcome studies of HR lowering in tachycardia-related hypertension. This review outlines the underlying mechanisms of early course hypertension pathophysiology with the critical role of the sympathetic nervous system activation, the prognostic significance of fast HR and the mechanistic rationale for the use of non-pharmacological approaches and/or highly long-acting cardioselective beta-blockers with some consideration given to betaxolol properties.

Keywords: essential hypertensiontachycardiacardiac outputperipheral resistancemuscle sympathetic nerve activitynon-pharmacological approachesbetaxolol

Article available in PDF format

View PDF Download PDF file

References

  1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; 137(12): e67–e6e492.
    CrossRefPubMed
  2. Niklas AA, Flotyńska A, Zdrojewski T, et al. Trends in hypertension prevalence, awareness, treatment, and control among Polish adults 75 years and older during 2007-2014. Cardiol J. 2018; 25(3): 333–344.
    CrossRefPubMed
  3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): 1269–1324.
  4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360(9349): 1903–1913.
    PubMed
  5. Julius S. The association of tachycardia with obesity and elevated blood pressure. J Pediatr. 2002; 140(6): 643–645.
    CrossRefPubMed
  6. Palatini P, Rosei EA, Casiglia E, et al. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. J Hypertens. 2016; 34(5): 813–821.
    CrossRefPubMed
  7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36(10): 1953–2041.
    CrossRefPubMed
  8. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982; 62(2): 347–504.
    CrossRef
  9. Julius S, Krause L, Schork N, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991; 9(1): 77–84.
    CrossRef
  10. Esler M, Jennings G, Biviano B, et al. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986; 8 Suppl 5: S39–S43.
    PubMed
  11. Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997; 30(5): 1267–1273.
    PubMed
  12. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens. 1997; 11 Suppl 1: S19–S27.
    PubMed
  13. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993; 125(4): 1148–1154.
    PubMed
  14. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999; 33(1): 44–52.
    PubMed
  15. Thomas F, Bean K, Provost JC, et al. Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age. J Hypertens. 2001; 19(5): 863–869.
    PubMed
  16. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010; 55(2): 567–574.
    CrossRefPubMed
  17. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens. 1996; 9(11): 113S–120S.
    PubMed
  18. Kannel WB, Kannel C, Paffenbarger RS, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987; 113(6): 1489–1494.
    PubMed
  19. Esler M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985). 2010; 108(2): 227–237.
    CrossRefPubMed
  20. Esler M, Lambert E, Schlaich M. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol (1985). 2010; 109(6): 1996–8; discussion 2016.
    CrossRefPubMed
  21. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge : quantitative assessment in human hypertensive disease. Circulation. 1999; 100(12): 1305–1310.
    PubMed
  22. Hering D, Kara T, Kucharska W, et al. High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests. Blood Press. 2013; 22(3): 183–187.
    CrossRefPubMed
  23. Hering D, Kara T, Kucharska W, et al. Longitudinal tracking of muscle sympathetic nerve activity and its relationship with blood pressure in subjects with prehypertension. Blood Press. 2016; 25(3): 184–192.
    CrossRefPubMed
  24. Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013; 61(2): 457–464.
    CrossRefPubMed
  25. Hering D, Marusic P, Walton AS, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014; 64(1): 118–124.
    CrossRefPubMed
  26. Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999; 34(4): 724–728.
    CrossRef
  27. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003; 108(5): 560–565.
    CrossRefPubMed
  28. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009; 53(2): 205–209.
    CrossRefPubMed
  29. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002; 105(11): 1354–1359.
    PubMed
  30. Guzzetti S, Piccaluga E, Casati R, et al. Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens. 1988; 6(9): 711–717.
    PubMed
  31. Narkiewicz K, Somers VK. Interactive effect of heart rate and muscle sympathetic nerve activity on blood pressure. Circulation. 1999; 100(25): 2514–2518.
    PubMed
  32. Grassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998; 16(11): 1635–1639.
    PubMed
  33. Salles GF, Cardoso CRL, Fonseca LL, et al. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens. 2013; 26(2): 218–226.
    CrossRefPubMed
  34. Hering D, Kucharska W, Kara T, et al. Resting sympathetic outflow does not predict the morning blood pressure surge in hypertension. J Hypertens. 2011; 29(12): 2381–2386.
    CrossRefPubMed
  35. Palatini P, Reboldi G, Beilin LJ, et al. Masked tachycardia. A predictor of adverse outcome in hypertension. J Hypertens. 2017; 35(3): 487–492.
    CrossRefPubMed
  36. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005; 352(19): 1951–1958.
    CrossRefPubMed
  37. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006; 27(1): 65–75.
    CrossRefPubMed
  38. Aune D, Sen A, ó'Hartaigh B, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017; 27(6): 504–517.
    CrossRefPubMed
  39. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004; 17(11 Pt 1): 1005–1010.
    CrossRefPubMed
  40. Hozawa A, Inoue R, Ohkubo T, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008; 26(8): 1571–1576.
    CrossRefPubMed
  41. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012; 109(5): 685–692.
    CrossRefPubMed
  42. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997; 15(1): 3–17.
    CrossRef
  43. Zhong C, Zhong X, Xu T, et al. Combined effects of hypertension and heart rate on the risk of stroke and coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China. Hypertens Res. 2015; 38(12): 883–888.
    CrossRefPubMed
  44. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001; 104(13): 1477–1482.
    PubMed
  45. Palatini P, Reboldi G, Beilin LJ, et al. Masked tachycardia. A predictor of adverse outcome in hypertension. J Hypertens. 2017; 35(3): 487–492.
    CrossRefPubMed
  46. Hering D, Grassi G. Prognostic significance of masked tachycardia in hypertension: evidence from a prospective international registry. J Hypertens. 2017; 35(3): 468–470.
    CrossRefPubMed
  47. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007; 100(8): 1254–1262.
    CrossRefPubMed
  48. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008; 52(18): 1482–1489.
    CrossRefPubMed
  49. Ripley TL, Saseen JJ. Beta-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014; 48(6): 723–733.
    CrossRefPubMed
  50. Carlberg Bo, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004; 364(9446): 1684–1689.
    CrossRefPubMed
  51. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol. 2014; 30(5 Suppl): S16–S22.
    CrossRefPubMed
  52. Kuyper LM, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014; 30(5 Suppl): S47–S53.
    CrossRefPubMed
  53. Tucker WD, Theetha Kariyanna P. Selective Beta-1-Blockers. In: StatPearls. Treasure Island, FL. 2018.
  54. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001; 37(2): 250–254.
    PubMed
  55. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557): 201–207.
    CrossRefPubMed
  56. Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur J Heart Fail. 2001; 3(3): 343–349.
    PubMed
  57. Stoschitzky K. Individual beta-blockers for individual patients. An article from the E-Journal of the ESC Council for Cardiology Practice. Vol. 6, N° 19. ; 15: Jan.
  58. Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991; 43(2): 203–242.
    PubMed
  59. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999; 55(2): 111–115.
    PubMed
  60. Stoschitzky K, Stoschitzky G, Brussee H, et al. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology. 2006; 106(4): 199–206.
    CrossRefPubMed
  61. Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry. 1998; 10(1): 9–14.
    PubMed
  62. Kunka RL, Wong YY, Andersen RL, et al. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels. Ther Drug Monit. 1989; 11(5): 523–527.
    PubMed
  63. Jacobs MC, Lenders JW, Smits P, et al. Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension. J Cardiovasc Pharmacol. 1997; 30(3): 338–342.
    PubMed
  64. Sundlöf G, Wallin BG, Strömgren E, et al. Acute effects of metoprolol on muscle sympathetic activity in hypertensive humans. Hypertension. 1983; 5(5): 749–756.
    PubMed
  65. Cogliati C, Colombo S, Ruscone TG, et al. Acute beta-blockade increases muscle sympathetic activity and modifies its frequency distribution. Circulation. 2004; 110(18): 2786–2791.
    CrossRefPubMed
  66. Wallin BG, Sundlöf G, Strömgren E, et al. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984; 6(4): 557–562.
    PubMed
  67. Burns J, Mary DA, Mackintosh AF, et al. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension. 2004; 44(4): 454–458.
    CrossRefPubMed
  68. Hering D, Kucharska W, Chrostowska M, et al. Age-dependent sympathetic neural responses to ß selective beta-blockade in untreated hypertension-related tachycardia. Blood Press. 2018; 27(3): 158–165.
    CrossRefPubMed
  69. Boutroy MJ, Morselli PL, Bianchetti G, et al. Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy. Eur J Clin Pharmacol. 1990; 38(6): 535–539.
    PubMed
  70. Huang YL, Lai CC, Wang YH, et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2987–2996.
    CrossRefPubMed
  71. Levy WC, Cerqueira MD, Harp GD, et al. Effect of endurance exercise training on heart rate variability at rest in healthy young and older men. Am J Cardiol. 1998; 82(10): 1236–1241.
    PubMed
  72. Wilmore J, Stanforth P, Gagnon J, et al. Heart rate and blood pressure changes with endurance training: The HERITAGE Family Study. Med Scien Sports Exercise. 2001: 107–116.
    CrossRef
  73. Carter JB, Banister EW, Blaber AP. Effect of endurance exercise on autonomic control of heart rate. Sports Med. 2003; 33(1): 33–46.
    CrossRefPubMed
  74. Perini R, Tironi A, Cautero M, et al. Seasonal training and heart rate and blood pressure variabilities in young swimmers. Eur J Appl Physiol. 2006; 97(4): 395–403.
    CrossRefPubMed
  75. Cozza IC, Di Sacco THR, Mazon JH, et al. Physical exercise improves cardiac autonomic modulation in hypertensive patients independently of angiotensin-converting enzyme inhibitor treatment. Hypertens Res. 2012; 35(1): 82–87.
    CrossRefPubMed
  76. Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med. 2007; 167(22): 2453–2460.
    CrossRefPubMed
  77. Rossi A, Dikareva A, Bacon SL, et al. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens. 2012; 30(7): 1277–1288.
    CrossRefPubMed
  78. Leggio M, Bendini MG, D'Emidio S, et al. Exercise dose in clinical practice: Right is better than more. Cardiol J. 2018; 25(2): 287–288.
    CrossRefPubMed
  79. Kaleta AM, Lewicka E. Exercise dose in clinical practice: Should safety limits be set? Cardiol J. 2018; 25(2): 289–290.
    CrossRefPubMed
  80. Rossi RC, Vanderlei LC, Gonçalves AC, et al. Impact of obesity on autonomic modulation, heart rate and blood pressure in obese young people. Auton Neurosci. 2015; 193: 138–141.
    CrossRefPubMed
  81. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018; 20(12): 2840–2851.
    CrossRefPubMed
  82. Wasmund SL, Owan T, Yanowitz FG, et al. Improved heart rate recovery after marked weight loss induced by gastric bypass surgery: two-year follow up in the Utah Obesity Study. Heart Rhythm. 2011; 8(1): 84–90.
    CrossRefPubMed
  83. Lambert EA, Sari CI, Eikelis N, et al. Effects of moxonidine and low-calorie diet: cardiometabolic benefits from combination of both therapies. Obesity (Silver Spring). 2017; 25(11): 1894–1902.
    CrossRefPubMed
  84. Hering D, Somers VK, Kara T, et al. Sympathetic neural responses to smoking are age dependent. J Hypertens. 2006; 24(4): 691–695.
    CrossRefPubMed
  85. Hering D, Kucharska W, Kara T, et al. Smoking is associated with chronic sympathetic activation in hypertension. Blood Press. 2010; 19(3): 152–155.
    CrossRefPubMed
  86. Persico AM. Persistent decrease in heart rate after smoking cessation: a 1-year follow-up study. Psychopharmacology (Berl). 1992; 106(3): 397–400.
    PubMed
  87. Harte CB, Meston CM. Effects of smoking cessation on heart rate variability among long-term male smokers. Int J Behav Med. 2014; 21(2): 302–309.
    CrossRefPubMed
  88. Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015; 350: h1551.
    CrossRefPubMed
  89. Hering D, Lachowska K, Schlaich M. Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease. Curr Hypertens Rep. 2015; 17(10): 80.
    CrossRefPubMed
  90. Schneider RH, Grim CE, Rainforth MV, et al. Stress reduction in the secondary prevention of cardiovascular disease: randomized, controlled trial of transcendental meditation and health education in Blacks. Circ Cardiovasc Qual Outcomes. 2012; 5(6): 750–758.
    CrossRefPubMed
  91. Tyagi A, Cohen M. Yoga and heart rate variability: A comprehensive review of the literature. Int J Yoga. 2016; 9(2): 97–113.
    CrossRefPubMed
  92. Hering D, Kucharska W, Kara T, et al. Effects of acute and long-term slow breathing exercise on muscle sympathetic nerve activity in untreated male patients with hypertension. J Hypertens. 2013; 31(4): 739–746.
    CrossRefPubMed
  93. Lachowska K, Bellwon J, Narkiewicz K, et al. Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction. Clin Res Cardiol. 2019; 108(1): 48–60.
    CrossRefPubMed
  94. Lachowska K, Bellwon J, Moryś J, et al. Slow breathing improves cardiovascular reactivity to mental stress and health-related quality of life in heart failure patients with reduced ejection fraction. Cardiol J. 2019 [Epub ahead of print].
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Cardiology Journal

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice